Evidence map›Paper›PMID 32796768›Full record

ArticleMolecules (Basel, Switzerland)2020

Transport Oligonucleotides-A Novel System for Intracellular Delivery of Antisense Therapeutics.

Oleg V Markov, Anton V Filatov, Maxim S Kupryushkin, Ivan V Chernikov, Olga A Patutina, Anton A Strunov, Elena L Chernolovskaya, Valentin V Vlassov, Dmitrii V Pyshnyi, Marina A Zenkova

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Oleg V MarkovInstitute of Chemical Biology and Fundamental Medicine SB RAS, Lavrentieva ave. 8, 630090 Novosibirsk, Russia.
Anton V FilatovInstitute of Chemical Biology and Fundamental Medicine SB RAS, Lavrentieva ave. 8, 630090 Novosibirsk, Russia.
Maxim S KupryushkinInstitute of Chemical Biology and Fundamental Medicine SB RAS, Lavrentieva ave. 8, 630090 Novosibirsk, Russia.
Ivan V ChernikovInstitute of Chemical Biology and Fundamental Medicine SB RAS, Lavrentieva ave. 8, 630090 Novosibirsk, Russia.
Olga A PatutinaInstitute of Chemical Biology and Fundamental Medicine SB RAS, Lavrentieva ave. 8, 630090 Novosibirsk, Russia.
Anton A StrunovInstitute of Cytology and Genetics SB RAS, Lavrentieva ave. 10, 630090 Novosibirsk, Russia.
Elena L ChernolovskayaInstitute of Chemical Biology and Fundamental Medicine SB RAS, Lavrentieva ave. 8, 630090 Novosibirsk, Russia.
Valentin V VlassovInstitute of Chemical Biology and Fundamental Medicine SB RAS, Lavrentieva ave. 8, 630090 Novosibirsk, Russia.
Dmitrii V PyshnyiInstitute of Chemical Biology and Fundamental Medicine SB RAS, Lavrentieva ave. 8, 630090 Novosibirsk, Russia.
Marina A ZenkovaInstitute of Chemical Biology and Fundamental Medicine SB RAS, Lavrentieva ave. 8, 630090 Novosibirsk, Russia.
Institute of Chemical Biology and Fundamental Medicine · RUInstitute of Cytology and Genetics · RU

Funding

Russian Science Foundation 19-74-30011Russian State funded budget АААА-А17-117020210021-7
6 · The paper itself

Abstract

Biological activity of antisense oligonucleotides (asON), especially those with a neutral backbone, is often attenuated by poor cellular accumulation. In the present proof-of-concept study, we propose a novel delivery system for asONs which implies the delivery of modified antisense oligonucleotides by so-called transport oligonucleotides (tON), which are oligodeoxyribonucleotides complementary to asON conjugated with hydrophobic dodecyl moieties. Two types of tONs, bearing at the 5'-end up to three dodecyl residues attached through non-nucleotide inserts (TD series) or anchored directly to internucleotidic phosphate (TP series), were synthesized. tONs with three dodecyl residues efficiently delivered asON to cells without any signs of cytotoxicity and provided a transfection efficacy comparable to that achieved using Lipofectamine 2000. We found that, in the case of tON with three dodecyl residues, some tON/asON duplexes were excreted from the cells within extracellular vesicles at late stages of transfection. We confirmed the high efficacy of the novel and demonstrated that

Indexed as

Drug Delivery SystemsAntineoplastic Agents, PhytogenicATP Binding Cassette Transporter, Subfamily BHumansNeoplasmsOligonucleotides, AntisenseRNA, MessengerTumor Cells, CulturedVinblastineABCB1 protein, humanAntineoplastic Agents, PhytogenicATP Binding Cassette Transporter, Subfamily BOligonucleotides, AntisenseRNA, MessengerVinblastineantisense oligonucleotidedeliverylipophilic oligonucleotide conjugatesmultiple drug resistancetransport oligonucleotide

Identifiers

PMID32796768
PMCPMC7464317
OpenAlexW3048751131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.